Despite a general decline in the S&P/ASX 200 Index on Thursday afternoon, several individual Australian Securities Exchange (ASX) shares are defying the trend, demonstrating significant upward momentum. The benchmark index was down 0.45% to 8,925.1 points at the time of reporting.

Actinogen Medical Sees Strong Investor Interest

Actinogen Medical Ltd (ASX: ACW) experienced a notable surge, with its share price climbing 9% to 3.5 cents. This advance is attributed to positive developments concerning its pivotal XanaMIA clinical trial for Alzheimer’s disease. The company announced it has received its third consecutive recommendation from the Data Monitoring Committee, signaling favorable trial progress.

Dr. Steven Gourlay, CEO of Actinogen, expressed confidence following the latest independent safety review. “With the third positive independent safety review complete, we are confident of the suitability of Xanamem for longer-term treatment,” Dr. Gourlay stated. He further elaborated on the drug’s potential, noting, “Xanamem has the potential to be a game-changer for Alzheimer’s disease given its potential product profile as a safe and effective oral medication with the ability to slow disease course progression significantly more than any approved therapy.”

Devex Resources Gains on Broker Speculation

Devex Resources Ltd (ASX: DEV) saw its share price jump over 10% to 28.2 cents. This movement appears to be largely influenced by a positive analyst report issued by Bell Potter this morning. The brokerage firm initiated coverage on the uranium developer with a speculative buy rating and set a price target of 41 cents.

Bell Potter’s analysis highlighted key value drivers for Devex Resources, including robust uranium market fundamentals, promising exploration results, and potential for mergers and acquisitions-driven growth. The report indicated a positive outlook for the uranium market in the medium to long term, citing factors such as barriers to new supply and increasing demand driven by electrification, energy security concerns, and the power requirements associated with artificial intelligence.

Electro Optic Systems Holdings Pauses Trading Amid Contract News

Electro Optic Systems Holdings Ltd (ASX: EOS) saw its share price rise 5% to $9.34 before its trading was temporarily halted. The defence and space company requested the trading halt pending an announcement regarding significant contractual developments.

In a statement regarding the trading halt, EOS indicated it pertains to the impending disclosure of a material contract for the sale of Remote Weapon Systems and a separate material contract to establish a joint venture. The company is currently finalizing the details of these announcements.

Web Travel Group Advances Without Specific News

Web Travel Group Ltd (ASX: WEB) recorded a 2.5% increase in its share price, reaching $3.09. Notably, there was no specific company news released to explain this rise. However, market observers suggest that investors may be anticipating improved trading conditions in the fiscal year 2027. This optimism could be linked to recent confirmations of a peace deal between the US and Iran, potentially leading to a more stable global economic environment and increased travel activity.